Evidence map›Paper›PMID 34762687›Full record

ArticlePloS one2021

The PINK1-Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells.

Aaron V Bradshaw, Philip Campbell, Anthony H V Schapira, Huw R Morris, Jan-Willem Taanman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Phytochemicals: Targeting Mitophagy to Treat Metabolic Disorders.Frontiers in cell and developmental biology · 2021
    Review
  17. Targeting mitophagy in Parkinson's disease.The Journal of biological chemistry
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aaron V BradshawDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Philip CampbellDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID 0000-0002-1357-9256
Anthony H V SchapiraDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Huw R MorrisDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Jan-Willem TaanmanDepartment of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID 0000-0002-5476-9785
National Hospital for Neurology and Neurosurgery · GB

Funding

Medical Research Council MR/M006646/1
6 · The paper itself

Abstract

Mutations in the PINK1 and PRKN genes are the most common cause of early-onset familial Parkinson disease. These genes code for the PINK1 and Parkin proteins, respectively, which are involved in the degradation of dysfunctional mitochondria through mitophagy. An early step in PINK1 -Parkin mediated mitophagy is the ubiquitination of the mitofusin proteins MFN1 and -2. The ubiquitination of MFN1 and -2 in patient samples may therefore serve as a biomarker to determine the functional effects of PINK1 and PRKN mutations, and to screen idiopathic patients for potential mitophagy defects. We aimed to characterise the expression of the PINK1 -Parkin mitophagy machinery in peripheral blood mononuclear cells (PBMCs) and assess if these cells could serve as a platform to evaluate mitophagy via analysis of MFN1 and -2 ubiquitination. Mitophagy was induced through mitochondrial depolarisation by treatment with the protonophore CCCP and ubiquitinated MFN proteins were analysed by western blotting. In addition, PINK1 and PRKN mRNA and protein expression levels were characterised with reverse transcriptase quantitative PCR and western blotting, respectively. Whilst CCCP treatment led to MFN ubiquitination in primary fibroblasts, SH-SY5Y neuroblastoma cells and Jurkat leukaemic cells, treatment of PBMCs did not induce ubiquitination of MFN. PRKN mRNA and protein was readily detectable in PBMCs at comparable levels to those observed in Jurkat and fibroblast cells. In contrast, PINK1 protein was undetectable and PINK1 mRNA levels were remarkably low in control PBMCs. Our findings suggest that the PINK1 -Parkin mitophagy signalling pathway is not functional in PBMCs. Therefore, PBMCs are not a suitable biosample for analysis of mitophagy function in Parkinson disease patients.

Indexed as

GTP PhosphohydrolasesLeukocytes, MononuclearMitophagyProtein KinasesSignal TransductionUbiquitinationUbiquitin-Protein LigasesCarbonyl Cyanide m-Chlorophenyl HydrazoneHumansJurkat CellsMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial ProteinsParkinson DiseasePTEN-Induced Putative KinaseCarbonyl Cyanide m-Chlorophenyl HydrazoneGTP PhosphohydrolasesMfn1 protein, humanMFN2 protein, humanMitochondrial Membrane Transport ProteinsMitochondrial Proteinsparkin proteinProtein KinasesPTEN-Induced Putative KinaseUbiquitin-Protein Ligases

Identifiers

PMID34762687
PMCPMC8584748
OpenAlexW3213665257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.